Previous Close | 12.52 |
Open | 12.49 |
Bid | 11.80 x 500 |
Ask | 11.86 x 500 |
Day's Range | 11.81 - 12.49 |
52 Week Range | 5.67 - 30.99 |
Volume | |
Avg. Volume | 1,185,973 |
Market Cap | 616.679M |
Beta (5Y Monthly) | 1.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an a
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026 – – Company to host R&D Day in New York on June 26, 2024 – WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – – Conference call to discuss the results to be held at 8:00 a.m. ET – WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of pat